Leadership Overview
Sarepta Therapeutics has 7 executives leading key functions including information technology, chief of staff, marketing operations, medical operations, operations, human resources, and executive leadership.
Driven by a commitment to innovation, Sarepta Therapeutics focuses on discovering, developing, and commercializing precision genetic medicines for rare diseases, aiming to transform patient lives globally through its advanced therapeutic platforms.
Driven by a commitment to innovation, Sarepta Therapeutics focuses on discovering, developing, and commercializing precision genetic medicines for rare diseases, aiming to transform patient lives globally through its advanced therapeutic platforms.
Leadership Roles at Sarepta Therapeutics
Brian Forsa - Vice President, Chief of Staff To Chief Executive Officer
Brian Forsa, the Vice President, Chief of Staff To Chief Executive Officer at Sarepta Therapeutics, provides strategic support and operational coordination directly to the CEO. Forsa manages key initiatives, facilitates cross-functional communication, and ensures the efficient execution of corporate objectives. This role involves bridging strategic planning with day-to-day operations, optimizing the CEO's effectiveness and driving critical projects forward. The Vice President, Chief of Staff To Chief Executive Officer plays a pivotal part in aligning leadership efforts with Sarepta's mission to deliver precision genetic medicines for rare diseases. Brian Forsa's responsibilities include preparing executive briefings, managing special projects, and enhancing organizational alignment across global teams. This position is crucial for maintaining momentum in the development and commercialization of Sarepta's innovative therapies.
Ian Estepan - President & Chief Operating Officer
Ian Estepan, the President & Chief Operating Officer at Sarepta Therapeutics, drives the company's global operational strategy and execution. Estepan oversees the day-to-day business functions, ensuring efficient production, supply chain management, and the successful commercialization of Sarepta's precision genetic medicines. This executive role is critical for scaling operations to meet the demands of a growing portfolio of treatments for rare diseases, including Duchenne muscular dystrophy. The President & Chief Operating Officer ensures that Sarepta's multi-platform Precision Genetic Medicine Engine operates at peak efficiency, supporting both approved therapies and the advancement of its broad pipeline. Ian Estepan's leadership focuses on operational excellence, regulatory compliance, and the strategic expansion of Sarepta's global presence across North America, Europe, and Asia, reinforcing the company's market leadership.
Louise Rodino-Klapac - President
Louise Rodino-Klapac, the President at Sarepta Therapeutics, directs the company's strategic vision and growth initiatives, particularly in advancing its gene therapy programs. Rodino-Klapac spearheads the development and commercialization of Sarepta's precision genetic medicines, focusing on transforming the lives of patients with rare neuromuscular and central nervous system disorders. This leadership role is central to driving innovation across Sarepta's multi-platform Precision Genetic Medicine Engine, including gene therapy, RNA-targeted therapeutics, and gene editing. The President ensures alignment across research, development, and commercial functions to accelerate the delivery of life-changing treatments. Louise Rodino-Klapac's expertise is critical in navigating the complex landscape of rare disease therapeutics and expanding Sarepta's global impact, reinforcing its position as a leader in the biopharmaceutical industry.
William Thornton - Chief Information Officer
William Thornton, the Chief Information Officer at Sarepta Therapeutics, directs the company's technology strategy and infrastructure. Thornton oversees all aspects of information systems, ensuring robust data security and efficient operational workflows that support Sarepta's biopharmaceutical research and development initiatives. This leadership role involves managing the technological backbone essential for advancing precision genetic medicines, from discovery through commercialization. Thornton's focus remains on leveraging cutting-edge technology to enhance productivity and facilitate the complex data management required for rare disease therapeutics. The Chief Information Officer ensures that Sarepta's digital environment is secure, scalable, and aligned with the company's mission to develop life-changing treatments for patients worldwide. William Thornton drives the integration of advanced IT solutions across all departments, supporting global operations and regulatory compliance.
Farzana Quddus - Principal Engineer & Chief Marketing Officer, Operation
Farzana Quddus, the Principal Engineer & Chief Marketing Officer, Operation at Sarepta Therapeutics, integrates engineering expertise with strategic marketing leadership. Quddus drives the operational aspects of marketing initiatives, ensuring that Sarepta's precision genetic medicines reach target patient populations effectively. This dual role focuses on the technical feasibility and market viability of therapeutic solutions for rare diseases. The Principal Engineer & Chief Marketing Officer, Operation oversees the strategic deployment of Sarepta's multi-platform Precision Genetic Medicine Engine, translating complex scientific advancements into accessible market strategies. Farzana Quddus's leadership ensures that operational efficiency supports the company's global commercialization efforts and pipeline development across neuromuscular and central nervous system disorders. Quddus champions data-driven marketing strategies informed by deep technical understanding.
Kirsten M. - Head of Medical Operations & Program Management, Global Medical Affairs Chief of Staff
Kirsten M., the Head of Medical Operations & Program Management, Global Medical Affairs Chief of Staff at Sarepta Therapeutics, directs the operational execution of global medical affairs strategies. M. oversees program management for critical medical initiatives, ensuring seamless coordination across diverse therapeutic areas, particularly in Duchenne muscular dystrophy and limb-girdle muscular dystrophies. This leadership position is vital for translating Sarepta's scientific breakthroughs into impactful patient support and medical education programs worldwide. The Head of Medical Operations & Program Management, Global Medical Affairs Chief of Staff ensures that medical operations align with the company's commitment to advancing precision genetic medicines. Kirsten M.'s responsibilities include optimizing resource allocation, managing project timelines, and fostering collaboration between research, development, and commercial teams to support FDA-approved treatments and pipeline expansion.
Alison Nasisi - Executive Vice President & Chief People Officer
Alison Nasisi, the Executive Vice President & Chief People Officer at Sarepta Therapeutics, leads all human capital strategies and organizational development initiatives. Nasisi is responsible for fostering a high-performance culture that supports Sarepta's mission to develop and commercialize innovative genetic medicines for rare diseases. This role involves attracting, retaining, and developing top talent across the company's global operations in North America, Europe, and Asia. The Executive Vice President & Chief People Officer ensures that Sarepta's workforce is equipped with the skills and resources necessary to advance its Precision Genetic Medicine Engine, encompassing gene therapy, RNA-targeted therapeutics, and gene editing. Alison Nasisi's strategic focus on people operations is integral to driving innovation and achieving Sarepta's long-term growth objectives in the biopharmaceutical sector.
Explore Leadership Teams in Manufacturing
Baxter International Inc. provides a portfolio of renal and hospital products. The company operates through two segments, Hospital Products and Renal. The Hospital Products segment manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics, and biosurgery products. This segment also provides products and services related to pharmacy compounding, drug formulation, and packaging technologies. The Renal segment provides products to treat end-stage renal disease, irreversible kidney failure, and acute kidney therapies. This segment offers products for various treatment continuums, such as technologies and therapies for peritoneal dialysis, hemodialysis, continuous renal replacement therapy, and additional dialysis services. The company sells its products for use in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors offices, and by patients at home under physician supervision.
Company Leadership
JA
JF
LP
Torrent Pharmaceuticals Ltd is the flagship enterprise of the Torrent Group and stands among the leading pharmaceutical companies in India, with a strong and growing international presence. The company is widely recognized for its leadership across key therapeutic areas, including cardiovascular health, central nervous system disorders, gastro-intestinal care, vitamins, minerals and nutritionals, and cosmo-dermatology, while also maintaining a meaningful footprint in diabetology, pain management, gynaecology, oncology and anti-infective treatments. Built on a foundation of scientific excellence and innovation, Torrent Pharma places research and development at the core of its strategy, supported by advanced infrastructure and a highly skilled scientific workforce dedicated to developing high-quality, affordable medicines for patients worldwide.
Company Leadership AJ
AV
VG
Organon creates, manufactures and markets innovative prescription medicines that improve the health and quality of human life. Through a combination of innovation and business partnerships, Organon seeks to leverage each of its core therapeutic fields.
Company Leadership
MC
MA
AL
Founded in 1995, The Ritedose Corporation is a manufacturing and packaging facility, located in Columbia, SC.
Company Leadership
JM
DM
Frequently Asked Questions Regarding Sarepta Therapeutics Top Executives and Leadership Team
Unlock more people and company data
